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Purpose: The side effects of radiotherapy induced on healthy tissue limit its use. To 
overcome this issue and fully exploit the potential of radiotherapy to treat cancers, the first- 
in-class radioenhancer NBTXR3 (functionalized hafnium oxide nanoparticles) has been 
designed to amplify the effects of radiotherapy.
Patients and Methods: Thanks to its physical mode of action, NBTXR3 has the potential 
to be used to treat any type of solid tumor. Here we demonstrate that NBTXR3 can be used 
to treat a wide variety of solid cancers. For this, we evaluated different parameters on a large 
panel of human cancer models, such as nanoparticle endocytosis, in vitro cell death induc-
tion, dispersion, and retention of NBTXR3 in the tumor tissue and tumor growth control.
Results: Whatever the model considered, we show that NBTXR3 was internalized by cancer 
cells and persisted within the tumors throughout radiotherapy treatment. NBTXR3 activated 
by radiotherapy was also more effective in destroying cancer cells and in controlling tumor 
growth than radiotherapy alone. Beyond the effects of NBTXR3 as single agent, we show 
that the antitumor efficacy of cisplatin-based chemoradiotherapy treatment was improved 
when combined with NBTXR3.
Conclusion: These data support that NBTXR3 could be universally used to treat solid 
cancers when radiotherapy is indicated, opening promising new therapeutic perspectives of 
treatment for the benefit of many patients.
Keywords: radiotherapy, radioenhancer, nanoparticle, NBTXR3, cancer
Introduction
Currently, approximately 50% of cancer patients will receive radiotherapy (RT) as part 
of their treatment.1 Despite progress in development of radiotherapeutic oncology, 
computer technology and medical imaging technology, the undesirable effects of RT on 
healthy peripheral tissues still limits the dose usable in patients. The recent develop-
ment of the first-in-class radioenhancer NBTXR3 (functionalized hafnium oxide 
nanoparticles) opened new avenues to address this major therapeutic issue. NBTXR3 
is administered by a single intratumoral injection before RT. Before RT, NBTXR3 is 
inert (“off” status) but during RT treatment, the high electron density of NBTXR3 
allows a high probability of interaction with incoming ionizing radiation, increasing 
energy dose deposit within cells (“on” status). Thanks to its physical mode of action, 
RT-activated NBTXR3 (NBTXR3+RT) is expected to be effective in all types of solid 
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tumors. NBTXR3 can therefore lead to either better efficacy 
with the same radiation dose2–4 or similar efficacy than RT 
with a lower radiation dose. Antitumor efficacy of NBTXR3 
+RT was demonstrated in a subset of tumors in preclinical 
settings,2,4 and more recently demonstrated clinically mean-
ingful benefit for patients with locally advanced Soft Tissue 
Sarcoma compared to RT alone, in the randomized controlled 
Phase II/III Act.in.Sarc study (NCT02379845).5 Other nano-
particles using atoms with high electron density, such as gold 
nanoparticles, eg, are currently under development in the 
field of radiotherapy.6–9
In this article, we sought to demonstrate that NBTXR3 
could be used to effectively treat any type of solid tumor, 
using a large panel of human tumors originating from 
different organs/tissues. We analyzed the capacity of 
these nanoparticles to be internalized by cancer cells and 
their retention within the tumors after intratumoral injec-
tion. We also studied the ability of NBTXR3+RT to 
improve cancer cell destruction and tumor growth control, 
compared to RT alone. In all the cancer cell lines tested 
here, NBTXR3+RT showed greater efficacy than RT alone. 
We also demonstrated that NBTXR3 can improve the 
efficiency of chemoradiation treatment with cisplatin 
(CDDP).
Materials and Methods
Cell Culture and Reagents
The human cancer cell lines Detroit 562 (#CCL-138, phar-
yngeal carcinoma), FaDu (#HTB-43, squamous cell phar-
yngeal carcinoma), HT1080 (#CCL-121, fibrosarcoma), 
MIA PaCa-2 (#CRL-1420, pancreas carcinoma), NCI- 
H460 (#HTB-177, large cell lung carcinoma) and T98G 
(#CRL-1690, glioblastoma) were purchased from ATCC. 
The human cancer cell lines CAL-33 (#ACC 447, tongue 
squamous cell carcinoma), DU-145 (#ACC 261, prostate 
carcinoma), HEP-3B (#ACC 93, hepatocellular carci-
noma), LNCaP (#ACC 256, prostate carcinoma) and PC- 
3 (#ACC 465, prostate adenocarcinoma) were purchased 
from DSMZ. The human cancer cell lines MDA-MB-231- 
luc-D3-H2LN (breast adenocarcinoma) and NCI-H460- 
Luc2 (large cell lung carcinoma) were purchased from 
Caliper. Cells were cultivated according to manufacturer’s 
recommendations and were controlled for mycoplasma by 
an independent laboratory (Clean Cells). NBTXR3 
(Nanobiotix) is a sterile aqueous suspension of functiona-
lized crystal hafnium oxide (HfO2) spherical nanoparticles 
with a size centered on 50nm, determined by dynamic 
light scattering technique (Zetasizer NanoZS, Malvern 
Instruments Ltd, Worcestershire, UK), bearing a marked 
negative surface charge (–50mV) in aqueous solution at 
pH 6–8,2,4 estimated by zeta potential analysis (Zetasizer 
NanoZS). Cisplatin (CDDP) was obtained from Sigma 
Aldrich.
Mice and Patient Derived Xenograft 
Models
Female immunodeficient NMRI-nu mice (6-weeks-old) 
were used for in vivo experiments (Janvier Labs), except 
for prostate cancer cell lines (PC-3, LNCaP, DU-145), 
where males have been used. For experiments with 
Patient Derived Xenograft LPS80T3 (obtained by direct 
transplantation of a poorly differentiated human grade 3 
retroperitoneal malignant fibrous histiocytoma) and PAC- 
120 (obtained from a hormone-dependent prostate primary 
adenocarcinoma) models, 8-weeks-old Hsd:Athymic nude- 
FOXn1 female and 5-weeks-old Hsd:Athymic nude- 
FOXn1 male were used, respectively (XenTech). Mice 
were maintained under pathogen-free conditions in the 
animal facility. All animal experiments were carried out 
in compliance with French and European laws and regula-
tions (European Directive 2010/63 EU). The local institu-
tional animal ethics board and French Ministère de la 
Recherche approved all mouse experiments.
Radiotherapy
For in vitro experiments, cells were irradiated at various 
doses according to the study, delivered as a single dose, 
using a 200kV X-ray source (NDI 226, Varian). For 
in vivo experiments, subcutaneous tumors were irradiated 
with various doses, using the same device as for in vitro 
experiments, excepted for PC-3 tumors irradiated using 
a 150kV X-ray source (CellRad, Faxitron), and NCI- 
H460 tumors irradiated using a 310kV X-ray source 
(Therapax, Agfa NDT). Selective irradiation of the tumor 
on mice was performed by the interposition of a lead 
shield, allowing full protection of the rest of the body, 
including proximal lymph nodes.
Uptake Analysis by Transmission 
Electronic Microscopy
Cells were seeded into 6-well plates (in duplicate) at the 
density of 20,000 cells/cm2. Once cells were attached to 
the plate, different doses of NBTXR3 were added over-
night, according to the cell line considered (ranging from 
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100µM to 800µM), as indicated on Figure 1. Cells were 
then pre-fixed with 2.5% glutaraldehyde in cacodylate 
0.1M at pH 7.4 (Sigma Aldrich) for 2 hours. Cells were 
subsequently post-fixed with 1% osmium tetroxide (Sigma 
Aldrich) for 45 minutes, washed and dehydrated in graded 
concentrations of ethanol (50%, 70%, 95% and 100%) 
(Sigma Aldrich). Cell samples were embedded with 
EPON (Oxford Instruments). The resin sample block was 
trimmed, 90µm thin sectioned to thickness of 70nm, (dia-
tome diamond knives, Euromedex). Thin sections (70nm) 
were collected onto 200 mesh cooper palladium grids, and 
counterstained with lead citrate before examination with 
a Zeiss EM 902 transmission electron microscope (TEM) 
at 80KV (UR 1196 GPL: Génomique et Physiologie de la 
Lactation - MIMA2 – plateau de Microscopie 
Electronique – Jouy-en-Josas). Microphotographs were 
acquired using MegaView III CCD camera and analyzed 
with ITEM software (Eloïse). Ten (10) cells were observed 
to estimate NBTXR3 nanoparticle cell uptake.
In vitro Cell Death Analysis
For clonogenic assays, cells were seeded in triplicate into 
6 well plates in a range of 200–10,000 cells/well depend-
ing on the test condition and radiation dose. Once cells 
were attached to the plate, 50µM to 800µM NBTXR3 was 
added. Different doses of X-rays were delivered 16 hours 
post NBTXR3 treatment. The cells were cultured up to 15 
±2 days at 37°C under 5% CO2. The colonies were fixed 
and stained with crystal violet (Sigma) (25% in EtOH) 
2 mL/well. All colonies of 50 cells or more were then 
counted. For clonogenic assay with NCI-H460-Luc2 cells, 
the same protocol was followed except that cells were 
exposed to 725nM of CDDP for 6 hours or 405nM of 
CDDP for 16 hours. Then, the medium was replaced by 
fresh medium without CDDP before irradiation.
Tumor Growth Control Experiments
For the in vivo tumor growth control assays, cells were 
subcutaneously injected into one flank of mice. Once the 
tumor had grown (50–120 mm3), mice were randomized to 
the different groups. A volume of NBTXR3 suspension (or 
vehicle) corresponding to 25% of the baseline tumor 
volume was injected into the tumor. After 24 hours, 
tumors were irradiated. The non-tumor parts of the mice 
were shielded by lead blocks. For chemoradiotherapy 
experiments with NCI-H460 cells, CDDP (1mg.kg−1) 
was administered by intraperitoneal injection two hours 
prior to RT, daily over 5 consecutive days. Length (L) 
and width (W) of tumors were measured 2–3 times per 
week using a digital caliper. Tumor volumes were calcu-
lated using the formula (L×W2/2).
In vivo µCT Analysis
MicroComputerized Tomography (µCT) was used for visua-
lization, evaluation of 3D dispersion and retention of 
NBTXR3 within the tumor. For µCT acquisition, mice 
were anesthetized using isoflurane (delivered as 1–3% for 
maintenance; up to 5% for induction) in oxygen from 
a precision vaporizer. Micro-CAT II CT scanner (Siemens) 
in which X-rays were generated at 80 kVp and 500 mA was 
used as imaging acquiring equipment (Voxcan).
Statistical Analysis
For the clonogenic assays, the studies have been indepen-
dently repeated at least three times. Results are expressed 
as mean of surviving fraction (SF) ± SD. The results were 
analyzed by one-way ANOVA. For in vivo CDDP experi-
mentation, tumor growth curve was analyzed using mixed 
linear modeling (MLM), performed with R statistics soft-
ware. GraphPad Prism 7.04 software was used to perform 
statistical analyzes. Significance was defined at the level of 
p<0.05.
Results
NBTXR3 is Endocytosed by Cancer Cells
The ability of tumor cell lines to internalize NBTXR3 
nanoparticles was assessed by TEM in eight cell lines 
originating from head and neck, lung, breast and prostate 
cancer (Figure 1, Table 1). In all these cell lines, nanopar-
ticles were systematically detected in the cytoplasm, where 
they formed clusters of various sizes distributed through-
out the cell. The amount of intracellular NBTXR3 greatly 
varied across the cell lines analyzed. Among the prostate 
cancer cell lines analyzed, PC-3 internalize the most, and 
LNCaP internalize the least of NBTXR3 nanoparticles 
(Figure S1). However, no nanoparticles were observed in 
the nuclei, regardless of the cell line considered.
RT-Activated NBTXR3 Kills Cancer Cells 
More Efficiently Than RT Alone
We sought to determine the impact of NBTXR3+RT on cell 
death induction, compared to RT alone. For this, we carried 
out clonogenicity tests on five cell lines originating from 
glioblastoma, prostate, liver, and pancreas cancers, varying 
the concentration of NBTXR3 (50–800µM) and the dose of 
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RT (1–6Gy) used (Figure 2, Table 1). No significant clono-
genic toxicity of NBTXR3 without RT was observed at the 
tested concentrations. For all cell lines studied, a NBTXR3 
dose-dependent increase in cell death was observed from 
2Gy, compared to RT alone. For some concentrations of 
NBTXR3, this difference becomes significant, compared to 
Figure 1 NBTXR3 nanoparticles are endocytosed by cancer cells and form clusters in the cytoplasm. Transmission electronic microscopy (TEM) representative images of 
NBTXR3 nanoparticles uptake, forming clusters in CAL-33, FaDu, NCI-H460-Luc2, MDA-MB-231-luc-D3-H2LN (upper panel) and DU-145, LNCaP, PC-3, Detroit 562 cells 
(lower panel). Cells were treated overnight with NBTXR3. 100µM, 400µM and 800µM indicate concentrations of NBTXR3 added to cells; arrows indicate NBTXR3 
clusters. 
Abbreviations: Cyt, cytoplasm; CTL, control cells (no NBTXR3); Nuc, nucleus.
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RT alone and an increase in the Dose Enhancement Factor 
(DEF) can be observed (Figure 2B).
Distribution and Retention of NBTXR3 in 
Tumor
The intended route of administration for NBTXR3 is a single 
intratumoral injection.5,10 For treatment with NBTXR3 to be 
effective, it is essential that the nanoparticles remain within the 
tumor throughout the RT sessions, whatever the type of solid 
tumor injected. Thus, we evaluated the dispersion and reten-
tion of NBTXR3 in various type of tumor at one day and 
several days after injection. To do this, we injected NBTXR3 
into subcutaneous tumors of six different mice models (cell 
lines and PDX), originating from lung, prostate, sarcoma, and 
head and neck cancers (Figure 3, Table 1). The high density of 
the nanoparticles renders them radio-opaque and easy to visua-
lize by µCT (Figure 3A). NBTXR3 localization was thus 
assessed the day after intratumoral injection (D02) and then 
at different post-injection time points (Figure 3B). These 
studies showed that, in all tumors, nanoparticles were found 
well distributed inside the tumor mass the day after intratu-
moral injection. The µCT performed one or two weeks after 
the injection showed that the nanoparticles were still localized 
in the tumor. Remarkably, in the PAC-120 PDX model, which 
has very slow tumor growth, the nanoparticles were still pre-
sent 50 days after the first µCT.
Table 1 Compilation of Preclinical Studies Performed with NBTXR3
Tissue Origin Cancer Type Cell Line Name In vitro In vivo
TEM Efficacy µCT Efficacy
Brain Glioblastoma 42MG-BA [2, 4] [4]
T98G ●
Breast Adenocarcinoma MDA-MB-231-luc-D3-H2LN ●
Colon Carcinoma CT26 [20] [20] [20]
HCT116 [2, 4] [4, 19] [2, 4] [2, 4]
Adenocarcinoma HT29 [4] [4]
Head and Neck Tongue squamous cell carcinoma CAL-33 ● [4] ● ●
Pharyngeal squamous cell carcinoma Detroit 562 ●
Hypopharyngeal squamous cell carcinoma FaDu ● ●, [4] ● ●
Liver Hepatocellular carcinoma HEP-3B ●
Lung Large cell lung carcinoma NCI-H460-Luc2 ● ●, [4] ● ●
Lung metastasis Fibrosarcoma Hs913T [4] [4]
Pancreas Carcinoma MIA PaCa-2 ●
Ductal adenocarcinoma PANC-1 [4] [4]
Prostate Carcinoma DU-145 ● ● ● ●
Adenocarcinoma LNCaP ●
PAC-120 ●
PC-3 ● ● ● ●
Soft tissue Rhabdomyosarcoma A673 [2, 4]
Fibrosarcoma HT1080 [2, 4] [2, 4] ●
Liposarcoma LPS80T3 ● ●
Notes: ● Studies presented in this article; blank boxes indicate that the study has not been done. References of previously published data are indicated in square brackets.
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Figure 2 NBTXR3 activated by RT kills more cancer cells than RT alone. (A) Clonogenic assay in DU-145, PC-3, HEP-3B (upper panel), T98G, and MIA PaCa-2 (lower panel). Cells 
were treated overnight with various concentrations of NBTXR3, then irradiated. After several days, colonies were stained using crystal violet and counted. Presented data were 
obtained from at least three independent experiments (n≥3). Data are represented as surviving fraction percentage (SF (%)) ± SEM. (B) Surviving fraction (SF) and corresponding 
Dose Enhancement Factor (DEF) for each condition. Percentage of surviving fraction (SF) ± SD and dose enhancement factor (DEF) ± SD. n ≥ 3. *p<0.05; **p<0.01; ***p<0.001. 
Abbreviation: N.D., not determined.
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Figure 3 After intratumoral injection, NBTXR3 distributes and remains in the tumor. (A) Thanks to its composition, NBTXR3 is easily observable in the tumor by µCT 
(white areas indicated by the arrows). (B) 3D representation of the of NBTXR3 nanoparticles distribution within tumor tissues of models NCI-H460-Luc2, PC-3 and 
LPS80T3 (upper panel), DU-145, FaDu (middle panel), CAL-33 and PAC-120 (lower panel), after µCT analysis. Indicated day corresponds to time post-intratumoral injection 
(D01).
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RT-Activated NBTXR3 Improves Tumor 
Growth Control
To confirm the ability of NBTXR3 to destroy tumor cells 
more efficiently than RT alone in vivo, we used seven 
human cell lines, derived from six distinct tumor types 
(tongue, prostate, pharynx, fibrosarcoma, liposarcoma and 
lung), subcutaneously injected in nude mice (Figure 4, 
Table 1). In the absence of RT, the injection of NBTXR3 
did not affect tumor growth, thus confirming the inert 
nature of these nanoparticles in their “off” status observed 
in vitro (Figure 4A and C). In contrast, treatment with 
NBTXR3+RT better controlled tumor growth and 
improved survival regardless of the model considered, 
compared to radiotherapy alone (Figure 4). NBTXR3+RT 
thus markedly increased the doubling time of tumor 
growth, the median survival, and reduced the optimal T/ 
C (Figure 4C). Only the FaDu and PC-3 models did not 
show an improvement in their median survival, but an 
increase in overall survival could still be observed 
(Figure 4A and C). In the well-known radioresistant DU- 
145 tumor model,11–13 RT (2x4Gy) had no significant 
effect on tumor growth. In stark contrast, the treatment 
of DU-145 tumors by RT-activated NBTXR3 resulted in 
a strong tumor growth delay. The tumor doubling time 
increased from 9 to 20 days, for RT and NBTXR3+RT, 
respectively (Figure 4A and C).
NBTXR3 Improves the Efficacy of 
Chemoradiotherapy with Cisplatin
We sought to determine the ability of NBTXR3 to improve 
the effectiveness of chemoradiation with cisplatin (CDDP 
+RT). We first performed clonogenicity tests using the 
NCI-H460-Luc2 cell line. Cells were treated with the 
CDDP 6h or 16h before RT, in the presence or not of 
NBTXR3, to highlight a possible time effect. The results 
show that NBTXR3+RT was as effective as CDDP+RT at 
destroying cancer cells (Figure 5A and B). Interestingly, 
the addition of NBTXR3 to CDDP+RT treatment signifi-
cantly improved cell destruction, whatever the time con-
sidered. We then compared the effects of RT, CDDP+RT, 
NBTXR3+RT and NBTXR3+CDDP+RT treatments on 
tumor growth control, in mice bearing an NCI-H460 
tumor (Figure 5C). The tumor growth delay was extended 
for mice receiving NBTXR3 activated by radiotherapy or 
Figure 4 NBTXR3 activated by radiotherapy controls tumor growth more effectively than radiotherapy alone. (A) The ability of NBTXR3 to control tumor growth better 
than radiotherapy as well as the impact on survival was tested in nude mice bearing a tumor of CAL-33, FaDu, LPS80T3, HT1080 (left column), DU-145, PC-3 and NCI- 
H460-Luc2 (right column). Number of mice per group: 5–6. Tumor growth curves are expressed as mean relative tumor volume (RTV) ± SEM. (B) Table indicative of the 
types of cancers tested, the doses of RT used and the source of radiotherapy. (C) Tumor doubling time, optimal T/C and median survival of the in vivo experiment results.
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Figure 5 RT-activated NBTXR3 improves the efficacy of cisplatin. The capacity of NBTXR3 to kill cancer cells, in combination or not with cisplatin (725nM of CDDP for 6 
hours or 405nM of CDDP for 16 hours), was analyzed by clonogenic assay on the NCI-H460-Luc2 cell line, after an incubation of 6h (A) or 16h (B) with cisplatin before 
irradiation. Presented data were obtained from five independent experiments (n=5). Data are represented as surviving fraction percentage (SF (%)) ± SEM. Surviving fraction 
(SF) and corresponding Dose Enhancement Factor (DEF) for each condition are indicated and time point are indicated on the lower panel. *p<0.05 vs CTL. (C) The ability of 
NBTXR3 to control tumor growth was compared in combination or not with cisplatin (CDDP, 1mg.kg−1). Tumor growth curves are expressed as mean tumor volume (TV) 
± SEM. Number of mice per group: 5.
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cisplatin and radiation, compared with mice receiving 
radiation alone (~17 days versus ~22 days,). Histology 
analyses revealed that NBTXR3+RT reduced cell prolif-
eration and induced apoptosis, similarly to CDDP+RT 
(Supplementary Materials and Methods and Figure S2). 
NBTXR3 +CDDP+RT treatment markedly prolonged 
tumor growth compared with RT alone (~17 days versus 
~25 days delay).
Discussion
The first-in-class nanosized radioenhancer NBTXR3 has 
been developed to multiply the effects of RT without 
generating additional side effects.5,10,14 Its effectiveness 
has been recently successfully demonstrated in a Phase 
II/III clinical study in locally advanced soft tissue 
sarcomas.5 In the preclinical studies presented in this arti-
cle, we wanted to demonstrate that NBTXR3 can be used 
to treat any type of solid cancer, and that its combination 
with chemoradiotherapy treatments can improve their 
effectiveness.
A cellular uptake of NBTXR3 was evidenced by TEM 
in all height cancer cell lines studied originating from 
different organs (pharynx, tongue, lung, breast, and pros-
tate). The number of nanoparticles detected in the cyto-
plasm varies depending on the cell line used, similar to 
previously published data.4 These differences cannot be 
explained by the organ origin of the cells, since such 
a difference can be observed between the PC-3 and 
LNCaP cell lines, both originating from prostate cancer 
(Figure S1). We hypothesize that this could be due to 
various internalization capacities between cell lines, eg, 
the clathrin-mediated endocytosis pathway, known to be 
an important entry point for internalization of 
nanoparticles,15 but additional analyses must be performed 
to confirm this. Another shared characteristic observed in 
TEM analysis was the capacity of all cell lines to form 
nanoparticle clusters in their cytoplasm. This concentra-
tion of the nanoparticles suggests a common intracellular 
trafficking mechanism. Autophagy may possibly explain 
nanoparticle aggregates because this process is frequently 
activated by nanoparticles.16 However, this may not be the 
only process involved since nanoparticle aggregates were 
also observed in the autophagy-deficient DU-145 cell line 
(Figure 1).17 Additional experiments are required to iden-
tify the endocytosis and intracellular trafficking pathways 
involved. In addition, nanoparticles have never been 
observed in the nucleus of cells, which could be explained 
by their size (centered on 50 nm). Indeed, it has previously 
been reported by Wu et al18 that only <50nm silver nano-
particles can enter the nucleus. Considering previously 
published results,2,4 the analyzes carried out in fourteen 
cell lines from ten different organs/tissues clearly show 
that the endocytosis of NBTXR3 nanoparticles, as well as 
their clustering and exclusion from the nucleus are char-
acteristics universally shared between cancer cell lines 
(Table 1).
All the clonogenic assays presented in this article show 
that NBTXR3+RT increased cancer cell death, in a dose- 
dependent manner, compared to the same dose of RT 
alone. Considering previous studies,2,4,19,20 the enhance-
ment of cell death following NBTXR3+RT treatment com-
pared to RT alone has now been demonstrated in fifteen 
different cancer cell lines originating from nine different 
organs/tissues (Figure 6, Table 1). This also clearly 
demonstrates that, thanks to its radioenhancing capacity, 
NBTXR3 can kill any type of cancer cell. It is assumed 
that this is also the case for any other solid tumor cancer 
cells. This superior capacity of NBTXR3 activated by RT 
to destroy cancer cells, compared to RT alone, could make 
it possible to reduce the dose per fraction, while maintain-
ing the same efficacy. This could have direct applications 
for patients, helping to limit the side effects of RT, thereby 
improving the patient’s quality of life and costs to the 
healthcare system. The improvement in cell death goes 
beyond a simple decrease in the number of cancer cells. 
Indeed, the heightened release of tumor-associated anti-
gens triggered by NBTXR3+RT treatment could play 
a critical role in the priming or amplification of the adap-
tive antitumor immune response, as recently reported in 
the CT26 mouse colorectal model.20
Preclinical and clinical studies have not revealed any 
leakage of NBTXR3 into surrounding tissues and showed 
that NBTXR3 remains within the tumor throughout RT 
treatment.2,10,20 To expand these results, we examined the 
retention of NBTXR3 in seven different tumor models by 
µCT. We demonstrate that NBTXR3 was detectable within 
the tumor from few days to several weeks after intratu-
moral injection. Considering previously published precli-
nical data, the retention of NBTXR3 nanoparticles in 
tumor has been demonstrated in nine different cancer cell 
lines originating from six different organs/tissues (Figure 
6, Table 1). We postulate that the “long-term” retention of 
NBTXR3 observed in these tumors could be due, at least 
in part, to the internalization of the nanoparticles by cells, 
as demonstrated in the different TEM analysis, but addi-
tional studies are needed to confirm this hypothesis. 
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Nonetheless, we can conclude that the distribution and 
retention of NBTXR3 in solid tumors are universal 
phenomena.
NBTXR3 nanoparticles have been designed to act as 
radioenhancers, only producing an antitumor effect when 
they receive ionizing radiation (“on” status). Without RT 
(“off” status), the nanoparticles are then “inert”. The dif-
ference between “off” and “on” status were previously 
reported2,4,19 and confirmed here by in vitro clonogenicity 
studies. These properties have also been demonstrated in -
vivo2,20 and confirmed by the new studies presented here. 
The “off” status of NBTXR3 had no effect on tumor 
growth, compared to the control, whatever the model 
considered. In contrary, the tumor growth control was 
systematically improved in the presence of NBTXR3+RT 
(“on” status), compared to RT alone, even in 
a radioresistant tumor model. These results are in good 
agreement with the previously published results2,5,20 and 
support the possibility that, thanks to its physical mode of 
action, the antitumor efficacy of NBTXR3 could be effi-
cient in any type of solid tumor.
Carcinoma of the lung is the leading cause of cancer- 
related death in both men and women,21 non-small cell 
lung cancer (NSCLC) accounting for almost 75% of 
cases.22 Concurrent chemoradiotherapy using cisplatin 
(CDDP) regimen is currently the standard treatment for 
stage III inoperable NSCLC.23,24 For elderly patients 
inoperable and too frail to support treatment with cispla-
tin, RT is the only therapeutic alternative, whose benefi-
cial effects are limited. Based on its very good safety 
profile reported in patients,10 NBTXR3 could open new 
avenues for the treatment of these particularly frail 
patients. In fact, the clonogenicity assays with CDDP or 
NBTXR3, in combination with RT, show that NBTXR3 
+RT is as efficient as CDDP+RT treatment to kill cancer 
cells. On the other hand, similar efficacies were obtained 
for both treatments in vivo. These promising results are 
now tested in a Phase I clinical trial to treat patients too 
frail to receive chemoradiotherapy with CDDP, and 
Figure 6 Review of studies with NBTXR3. The various experiments carried out in vitro and in vivo on the various human models demonstrated the effectiveness of 
NBTXR3 and its capacity to treat any kind of solid tumor. These preclinical results have been confirmed in a Phase II/III clinical trial in patients with soft tissue sarcoma, and 
other Phase I trials are currently in progress.
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eligible only for RT (NCT02901483). Remarkably, 
in vitro and in vivo results of CDDP+NBTXR3+RT 
show that this combination improved the efficacy of 
CDDP+RT. This suggests that patients usually treated 
with this chemoradiotherapy could benefit from the addi-
tion of NBTXR3 in their treatment. These results also 
open up interesting new perspectives concerning the com-
bination of NBTXR3 with other chemoradiotherapies, 
such as, g, poly(ADP-ribose)polymerase inhibitors 
(PARPi)25 or tyrosine kinase inhibitors (TKI).26 
NBTXR3 activated by RT may also be valuable in com-
binations with other therapies, such as immune checkpoint 
inhibitors like anti-PD-1. Indeed, we recently showed in 
immunocompetent mice that NBTXR3 activated by RT 
was able to induce an antitumor immune response, produ-
cing an abscopal effect.20
Taken together, the data presented so far support the 
possibility that NBTXR3 could be universally used with 
RT to treat any type of solid cancer.2,4,5,10,19,20 NBTXR3 
opens promising new therapeutic perspectives of treatment 
for the benefit of millions of patients. Several clinical trials 
in HNSCC, liver cancers, as a single agent, or in combina-
tion with chemotherapy in HNSCC and rectal cancer as well 
as in combination with anti-PD-1 in HNSCC, lung or liver 
metastasis from any primary cancer are currently in progress 
to confirm the important therapeutic potential of NBTXR3.
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